Coley Gets $50M Up Front In ProMune Alliance With Pfizer March 25, 2005 Coley Pharmaceutical Group Inc. entered a deal with Pfizer Inc. worth up to $505 million for its lead cancer drug, ProMune. (BioWorld Today)Read More